Substance / Medication

Etretinate

Overview

Active Ingredient
etretinate
RxNorm CUI
4182

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

145 trials linked to this intervention

145
Total Trials
25
Recruiting
61
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The epidermis mitochondria ultrastructure evaluation of the etretinate-treated white rat.
Budzyńska Beata, Budzyński Arkadiusz, Jedrych Barbara et al. · Ann Univ Mariae Curie Sklodowska Med · 2002
PMID: 12898836Observational
Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate.
Matsuda-Hirose Haruna, Sho Yuriko, Yamate Tomoko et al. · J Dermatol · 2020
PMID: 31840277Case Report
Effectiveness of etretinate/yokuinin combination therapy for lip squamous cell carcinoma.
Komori Takaya, Cho Maria, Inoue Akiha et al. · J Dermatol · 2019
PMID: 30035310Case Report
Inflammatory disseminated superficial porokeratosis successfully controlled with a combination of topical diclofenac gel and systemic etretinate.
Shimizu S, Takashima Y, Hotta M et al. · J Eur Acad Dermatol Venereol · 2018
PMID: 29194784Case Report
Successful etretinate treatment of recurrent keratoacanthomas on a skin graft: Case report.
Nishibaba Rie, Higashi Yuko, Mera Kentaro et al. · J Dermatol · 2017
PMID: 27178485Case Report
Successful combination therapy of low-dose vorinostat, etretinate and narrowband ultraviolet B irradiation for Sézary syndrome.
Uehara Jiro, Honma Masaru, Ohishi Yasushi et al. · J Dermatol · 2017
PMID: 27440107Case Report
Manifest hair repigmentation associated with etretinate therapy.
Nagase Kotaro, Inoue Takuya, Narisawa Yutaka · J Dermatol · 2017
PMID: 27401844Case Report
Low-dose etretinate shows promise in management of punctate palmoplantar keratoderma type 1: Case report and review of the published work.
Nomura Toshifumi, Moriuchi Reine, Takeda Masae et al. · J Dermatol · 2015
PMID: 25919143Case Report
Punctate palmoplantar keratoderma type 1: a novel AAGAB mutation and efficacy of etretinate.
Nomura Toshifumi, Yoneta Akihiro, Pohler Elizabeth et al. · Acta Derm Venereol · 2015
PMID: 24573067Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etretinate (substance)
SNOMED CT
386937001
UMLS CUI
C0015137
RxNorm CUI
4182

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
145
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.